See how EMET supports translational teams focused on indication strategy, biomarker planning, and evidence synthesis.
Translational capabilities
Explore a range of sample prompts and representative outputs from EMET across the workflows below.
We're advancing a TROP2-targeting ADC into Phase II NSCLC. Define a companion diagnostic biomarker strategy: identify which TROP2 expression levels, co-mutations, and immune features best predict response, and estimate the size of the enrichable patient population.
pubmed-literaturecbioportal-mutations
Given that VEGF pathway inhibitors are approved in oncology, what evidence supports their investigation in age-related macular degeneration or diabetic retinopathy?
We have a transcriptomic disease signature from ALS patient motor neurons (top 100 up/downregulated genes). Find FDA-approved drugs that reverse this signature using LINCS L1000 data, cross-check against neurological target safety, and rank by clinical precedent in neurodegenerative disease.
Use Mendelian randomization to test whether genetically elevated IL-6 signalling raises type 2 diabetes risk, map the lead IL6 eQTLs across tissues, and check whether any colocalize with T2D/glycemic GWAS loci.
Give me a comprehensive competitive intelligence report on KRAS G12C inhibitors. Cover: all active clinical trials by phase and sponsor, publication output over the past 3 years, patent filing trends, and differentiation between sotorasib, adagrasib, and emerging programmes.
What are the known adverse events and drug interactions for warfarin, and how do common genetic variants in CYP2C9 and VKORC1 influence its toxicity and dosing safety?
